Novartis Vaccines appoints medical affairs director in Europe; Bristol-Myers submits HIV NDA; Opioid scripts surging for pregnant women;

@FiercePharma: Top-read FP news this weekend: PhRMA defends Gilead's pricey Sovaldi as docs look forward to more hep C choices. Story | Follow @FiercePharma

@TracyStaton: FiercePharma's best-read marketing story: Sanofi aims for outcomes with new Chief Patient Officer. More | Follow @TracyStaton

@EricPFierce: Daiichi Sankyo lays out the roadmap for finalizing the Ranbaxy and Sun deal. News | Follow @EricPFierce

@CarlyHFierce: Editor's Corner: Vivus needs more than boardroom shuffling to keep up with Arena's Belviq. Article | Follow @CarlyHFierce

> Novartis Vaccines has appointed John Porter as its medical affairs director for northern Europe. Release

> The FDA has extended BioMarin's ($BMRN) market exclusivity for rare-disease drug Kuvan by 6 months. Release

> Bristol-Myers Squibb ($BMY) has submitted to the FDA an NDA for a fixed-dose combo tablet that treats HIV-1. Release

> The FDA has warned consumers that two herbal supplement weight-loss pills, Infinity and Lite Fit USA, contain a dangerous ingredient recalled from the market due to heart attack and stroke risks. More

> A new study shows the number of prescriptions for opioid painkillers for pregnant women is surging despite their unknown impact on developing fetuses. More (sub. req.)

Medical Device News

@FierceMedDev: Varian Medical pays $35M to settle Pitt patent spat. News | Follow @FierceMedDev

@VarunSaxena2: ICYMI last week: Deerfield bets on robotic surgery with OMNIlife science deal. Article | Follow @VarunSaxena2

@EmilyWFierce: Staples wants to make 3D printing mainstream with a new trial program in New York and L.A. More from MedCity News | Follow @EmilyWFierce

@MichaelGFierce: ICYMI: 'Computer' made with DNA nanorobots delivers compounds in live cockroach. Story from FierceDrugDelivery | Follow @MichaelGFierce

> Abbott wins FDA nod for diabetes blood test. News

> Report: Covidien buys New Wave Surgical for $100M+. Article

> Edwards wins a battle in its ongoing TAVR patent war with Medtronic. Report

> Covidien snags FDA OK for a camera-equipped feeding tube. Item

Biotech News

@FierceBiotech: JNJ teams with Scripps on a new Big Pharma/biotech spinoff matchmaking effort. Story | Follow @FierceBiotech

@JohnCFierce: Cytos hits self-destruct button as PhIIb asthma study bombs. More | Follow @JohnCFierce

@DamianFierce: Two biotech/med tech IPOs expected this week in Vital Therapies and TriVascular Technologies. Item | Follow @DamianFierce

@EmilyMFierce: Essential immune organ regenerated in mice. More | Follow @EmilyMFierce

> Intercept grabs the spotlight at EASL, builds case for lead drug OCA. News

> Novartis slams the brakes on RNAi development efforts. Brief

> J&J axes a late-stage Botox rival, chopping project staffers. Story

CRO News

> Clinipace cozies up to Karyopharm to get its pipeline moving. Story

> Parexel amps up its imaging focus in rebranded informatics biz. More

> Bristol-Myers enlists DKSH to push its drugs in Asia. Article

> Pacira picks Patheon to hit the gas on pain drug production. News

> Catalent inks a biosimilar alliance with a Chinese drugmaker. Report

> CROs are spending more on merit raises, survey says. Item

Biotech IT News

> PatientsLikeMe inks 5-year deal with Genentech. More

> Big Pharma companies open up cancer trial comparator arm data. Story

> Cheminformatics skills shortage threatens Indian drug discovery program. News

> Cancer foundation aiming to build a database of 50,000 human genomes. Report

> Pharma continues to grapple with trial participants' use of social media. Article

> NCI plans database of patients who experience miraculous recoveries. Item

And Finally... Pfizer's ($PFE) consumer healthcare unit has teamed up with actor Josh Duhamel for its Advil Relief in Action campaign, which features a Mobile Relief Center tour making about 100 stops across the country. More

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.